Loading stock analysis…
Evidence Synthesis
Last synthesized: 20 Oct 2026, 08:03
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
GENPHARMA posted a standard shift in its financial performance.
The company's gross margin accelerated to .54%, up from 0.57%.
Its marginal operating leverage also accelerated to .57%, up from 0.37%.
Revenue growth year-over-year increased to .8%, up from a previous value.
However, the close price decelerated to .01 INR, down from 1.07 INR.
The daily trading volume accelerated to 1,097,244 shares, up from 654,205 shares.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 7.54 % | 0.57 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 0.57 % | 0.37 | ▲ |
| REVENUE_GROWTH_YOY | 312.8 % | — | - |
| PRICE_CHANGE_PERCENT | -5.607 % | — | - |
| DAILY_VOLUME | 10,97,244 shares | 6,54,205 | ▲ |
| CLOSE_PRICE | 1.01 INR | 1.07 | ▼ |
Cite this
Source: Samhati evidence synthesis for GENPHARMA (2026-10-20). Observation: GENPHARMA posted a standard shift in its financial performance. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/genpharma
Filing step-changes